English

Iterum Therapeutics plc

EDGAR

ITRM Current report (8-K) · filed 2026-03-03

47 filing records in this dataset, filed from 2016-12-30 to 2026-03-03. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

390 thousand USD

2025 Q3 · USD

Exact inputs and evidence

Revenue: 390000 USD Source

Operating margin

-1,982.31%

2025 Q3 · %

Exact inputs and evidence

Operating Income: -7731000 USD Source
Revenue: 390000 USD Source

Operating cash flow

-7.45 million USD

2025 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -15258000 USD Source
Operating Cash Flow: -7811000 USD Source

Free cash flow

-7.46 million USD

2025 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -15258000 USD Source
Operating Cash Flow: -7811000 USD Source
Capital Expenditure: 14000 USD Source
Capital Expenditure: 2000 USD Source

Cash and cash equivalents: 11 million USD 2025-09-30 Source
Exact value

11002000 USD
Long-term debt including current maturities: 20 million USD 2025-09-30 Source
Exact value

20045000 USD
Shares outstanding: Not available

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-27 million USD

2024-10-01 – 2025-09-30

Exact inputs and evidence

Net income: -24774000 USD · 2024-01-01 – 2024-12-31 Source
Net income: -18192000 USD · 2024-01-01 – 2024-09-30 Source
Net income: -4891000 USD · 2025-01-01 – 2025-03-31 Source
Net income: -6509000 USD · 2025-04-01 – 2025-06-30 Source
Net income: -8979000 USD · 2025-07-01 – 2025-09-30 Source

Operating cash flow

-19.5 million USD

2024-10-01 – 2025-09-30

Exact inputs and evidence

Operating cash flow: -26770000 USD · 2024-01-01 – 2024-12-31 Source
Operating cash flow: -22514000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -3060000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -7811000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -3060000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -15258000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -7811000 USD · 2025-01-01 – 2025-06-30 Source

Capital expenditure

14 thousand USD

2024-10-01 – 2025-09-30

Exact inputs and evidence

Capital expenditure: 2000 USD · 2024-01-01 – 2024-12-31 Source
Capital expenditure: 2000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 2000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 2000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 2000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 14000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 2000 USD · 2025-01-01 – 2025-06-30 Source

Free cash flow

-19.5 million USD

2024-10-01 – 2025-09-30

Exact inputs and evidence

Operating cash flow: -26770000 USD · 2024-01-01 – 2024-12-31 Source
Operating cash flow: -22514000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -3060000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -7811000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -3060000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -15258000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -7811000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 2000 USD · 2024-01-01 – 2024-12-31 Source
Capital expenditure: 2000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 2000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 2000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 2000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 14000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 2000 USD · 2025-01-01 – 2025-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-03-03.

Financial data available through: 2024-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2021-12-31
Operating income: 9 of 11 periods available· newest 2024-12-31
Net income: 9 of 11 periods available· newest 2024-12-31
Operating cash flow: 9 of 11 periods available· newest 2024-12-31
Capital expenditure: 8 of 11 periods available· newest 2024-12-31
Total assets: 8 of 11 periods available· newest 2024-12-31
Total liabilities: 8 of 11 periods available· newest 2024-12-31
Current assets: 8 of 11 periods available· newest 2024-12-31
Current liabilities: 8 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 8 of 11 periods available· newest 2024-12-31
Long-term debt including current maturities: 4 of 11 periods available· newest 2024-12-31
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+USD 13.6 million

Prior period

−USD 38.37 million

2023-01-01 – 2023-12-31
Current period

−USD 24.77 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-24774000 − -38371000 = 13597000 USD

-38371000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-24774000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Iterum Therapeutics plc · 2024-12-31 Iterum Therapeutics plc (edgar:1659323) Year-over-year change in Net income: 13597000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -24774000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000119312525281557/itrm-20250930.htm#1041887 Filing: 000119312525281557 Input fundies:NetIncome: -38371000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2885213 Filing: 000095017025015857
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 12.56 million

Prior period

−USD 39.33 million

2023-01-01 – 2023-12-31
Current period

−USD 26.77 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-26770000 − -39330000 = 12560000 USD

-39330000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-26770000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Iterum Therapeutics plc · 2024-12-31 Iterum Therapeutics plc (edgar:1659323) Year-over-year change in Operating cash flow: 12560000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -26770000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2767620 Filing: 000095017025015857 Input fundies:OperatingCashFlow: -39330000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2769323 Filing: 000095017025015857
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-84.6%

Prior period

USD 13,000

2023-01-01 – 2023-12-31
Current period

USD 2,000

2024-01-01 – 2024-12-31

Exact inputs and evidence

2000 − 13000 = -11000 USD

13000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
2000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Iterum Therapeutics plc · 2024-12-31 Iterum Therapeutics plc (edgar:1659323) Year-over-year change in Capital expenditure: -11000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 2000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2776793 Filing: 000095017025015857 Input fundies:CapitalExpenditure: 13000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2778482 Filing: 000095017025015857
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue USD 0
Operating costs Derived USD 24.54 million
Operating income −USD 24.54 million
Tax, interest and other Derived USD 67.03 million
Net income −USD 91.56 million

Cash

Operating cash flow −USD 15.84 million
Capital expenditure USD 61,000
Free cash flow Derived −USD 15.9 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Not shown: operating income or net income is not reported.
2017 Operating loss: operating costs were 5,898% of revenue.
2018 Operating loss: operating costs were 8,910% of revenue.
2019 Operating loss: operating costs were 275,832% of revenue.
2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	0	13359000 Derived	-13359000	105000 Derived	-13464000	Unavailable	Source 2016-01-01 – 2016-12-31: 0 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -13359000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -13464000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -11298000 USD Inspect Operating Cash Flow Open source
2017 2017-01-01 – 2017-12-31	508000	29963000 Derived	-29455000	-49000 Derived	-29406000	-31416000 Derived	Source 2017-01-01 – 2017-12-31: 508000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -29455000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -29406000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -30604000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 812000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	869000	77428000 Derived	-76559000	497000 Derived	-77056000	-77342000 Derived	Source 2018-01-01 – 2018-12-31: 869000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -76559000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -77056000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -77252000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 90000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	37000	102058000 Derived	-102021000	1109000 Derived	-103130000	-81946000 Derived	Source 2019-01-01 – 2019-12-31: 37000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -102021000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -103130000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -81922000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 24000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	0	32126000 Derived	-32126000	19880000 Derived	-52006000	-54539000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -32126000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -52006000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -54528000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 11000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	0	24537000 Derived	-24537000	67027000 Derived	-91564000	-15903000 Derived	Source 2021-01-01 – 2021-12-31: 0 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -24537000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -91564000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -15842000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 61000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	0	Revenue: 0 Open source
20172017-12-31	Revenue	508000	Revenue: 508000 Open source
20182018-12-31	Revenue	869000	Revenue: 869000 Open source
20192019-12-31	Revenue	37000	Revenue: 37000 Open source
20202020-12-31	Revenue	0	Revenue: 0 Open source
20212021-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2020

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20172017-12-31	Year over year	No prior comparable period	Revenue: 508000 Open source Revenue: 0 Open source
20182018-12-31	Year over year	71.1%	Revenue: 869000 Open source Revenue: 508000 Open source
20192019-12-31	Year over year	-95.7%	Revenue: 37000 Open source Revenue: 869000 Open source
20202020-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 37000 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -275,732.4% 2019

Net margin -278,729.7% 2019

Free cash flow margin -221,475.7% 2019

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	Not reported	Operating Income: -13359000 Open source Revenue: 0 Open source
20172017-12-31	Operating margin	-5,798.2%	Operating Income: -29455000 Open source Revenue: 508000 Open source
20182018-12-31	Operating margin	-8,810%	Operating Income: -76559000 Open source Revenue: 869000 Open source
20192019-12-31	Operating margin	-275,732.4%	Operating Income: -102021000 Open source Revenue: 37000 Open source
20202020-12-31	Operating margin	Not reported	Operating Income: -32126000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	Not reported	Operating Income: -24537000 Open source Revenue: 0 Open source
20162016-12-31	Net margin	Not reported	Net Income: -13464000 Open source Revenue: 0 Open source
20172017-12-31	Net margin	-5,788.6%	Net Income: -29406000 Open source Revenue: 508000 Open source
20182018-12-31	Net margin	-8,867.2%	Net Income: -77056000 Open source Revenue: 869000 Open source
20192019-12-31	Net margin	-278,729.7%	Net Income: -103130000 Open source Revenue: 37000 Open source
20202020-12-31	Net margin	Not reported	Net Income: -52006000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	Not reported	Net Income: -91564000 Open source Revenue: 0 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -11298000 Open source
20172017-12-31	Free cash flow margin	-6,184.3%	Revenue: 508000 Open source Operating Cash Flow: -30604000 Open source Capital Expenditure: 812000 Open source
20182018-12-31	Free cash flow margin	-8,900.1%	Revenue: 869000 Open source Operating Cash Flow: -77252000 Open source Capital Expenditure: 90000 Open source
20192019-12-31	Free cash flow margin	-221,475.7%	Revenue: 37000 Open source Operating Cash Flow: -81922000 Open source Capital Expenditure: 24000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -54528000 Open source Capital Expenditure: 11000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -15842000 Open source Capital Expenditure: 61000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -15.8M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-11298000	Operating Cash Flow: -11298000 Open source
20172017-12-31	Operating cash flow	-30604000	Operating Cash Flow: -30604000 Open source
20182018-12-31	Operating cash flow	-77252000	Operating Cash Flow: -77252000 Open source
20192019-12-31	Operating cash flow	-81922000	Operating Cash Flow: -81922000 Open source
20202020-12-31	Operating cash flow	-54528000	Operating Cash Flow: -54528000 Open source
20212021-12-31	Operating cash flow	-15842000	Operating Cash Flow: -15842000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -15.9M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	Unavailable	Operating Cash Flow: -11298000 Open source
20172017-12-31	Free cash flow	-31416000	Operating Cash Flow: -30604000 Open source Capital Expenditure: 812000 Open source
20182018-12-31	Free cash flow	-77342000	Operating Cash Flow: -77252000 Open source Capital Expenditure: 90000 Open source
20192019-12-31	Free cash flow	-81946000	Operating Cash Flow: -81922000 Open source Capital Expenditure: 24000 Open source
20202020-12-31	Free cash flow	-54539000	Operating Cash Flow: -54528000 Open source Capital Expenditure: 11000 Open source
20212021-12-31	Free cash flow	-15903000	Operating Cash Flow: -15842000 Open source Capital Expenditure: 61000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

45.1% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Liabilities / assets	Not reported	No source recorded
20172017-12-31	Liabilities / assets	15.4%	Total Liabilities: 7206000 Open source Total Assets: 46757000 Open source
20182018-12-31	Liabilities / assets	26.8%	Total Liabilities: 26249000 Open source Total Assets: 97871000 Open source
20192019-12-31	Liabilities / assets	201.9%	Total Liabilities: 51989000 Open source Total Assets: 25751000 Open source
20202020-12-31	Liabilities / assets	254.2%	Total Liabilities: 83351000 Open source Total Assets: 32792000 Open source
20212021-12-31	Liabilities / assets	45.1%	Total Liabilities: 41275000 Open source Total Assets: 91509000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

6.43× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Current assets / current liabilities	Not reported	No source recorded
20172017-12-31	Current assets / current liabilities	6.2×	Current Assets: 44173000 Open source Current Liabilities: 7126000 Open source
20182018-12-31	Current assets / current liabilities	7.61×	Current Assets: 92971000 Open source Current Liabilities: 12219000 Open source
20192019-12-31	Current assets / current liabilities	0.32×	Current Assets: 11718000 Open source Current Liabilities: 36986000 Open source
20202020-12-31	Current assets / current liabilities	0.51×	Current Assets: 21472000 Open source Current Liabilities: 41698000 Open source
20212021-12-31	Current assets / current liabilities	6.43×	Current Assets: 83266000 Open source Current Liabilities: 12941000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 13.46 million Exact value Exact value: -13464000 USD 2016-01-01 – 2016-12-31: -13464000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Iterum Therapeutics plc · 2016-12-31 Iterum Therapeutics plc (edgar:1659323) Net Income: -13464000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -13464000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000156459019009089/itrm-20181231.xml#119727 Filing: 000156459019009089 The citation records this snapshot. The page link may show a newer release later.	−USD 11.3 million Exact value Exact value: -11298000 USD 2016-01-01 – 2016-12-31: -11298000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Iterum Therapeutics plc · 2016-12-31 Iterum Therapeutics plc (edgar:1659323) Operating Cash Flow: -11298000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11298000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000156459019009089/itrm-20181231.xml#146623 Filing: 000156459019009089 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2017 2017-01-01 – 2017-12-31	−USD 29.41 million Exact value Exact value: -29406000 USD 2017-01-01 – 2017-12-31: -29406000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Iterum Therapeutics plc · 2017-12-31 Iterum Therapeutics plc (edgar:1659323) Net Income: -29406000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29406000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000156459020010242/itrm-20191231.xml#149715 Filing: 000156459020010242 The citation records this snapshot. The page link may show a newer release later.	−USD 30.6 million Exact value Exact value: -30604000 USD 2017-01-01 – 2017-12-31: -30604000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Iterum Therapeutics plc · 2017-12-31 Iterum Therapeutics plc (edgar:1659323) Operating Cash Flow: -30604000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -30604000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000156459020010242/itrm-20191231.xml#178122 Filing: 000156459020010242 The citation records this snapshot. The page link may show a newer release later.	USD 812,000 Exact value Exact value: 812000 USD 2017-01-01 – 2017-12-31: 812000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Iterum Therapeutics plc · 2017-12-31 Iterum Therapeutics plc (edgar:1659323) Capital Expenditure: 812000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 812000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000156459020010242/itrm-20191231.xml#178750 Filing: 000156459020010242 The citation records this snapshot. The page link may show a newer release later.	−USD 31.42 million Calculation and evidence -30604000 − 812000 USD Exact free cash flow: -31416000 USD 2017-01-01 – 2017-12-31: -30604000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 812000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Iterum Therapeutics plc · 2017-12-31 Iterum Therapeutics plc (edgar:1659323) Free cash flow: -31416000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -30604000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000156459020010242/itrm-20191231.xml#178122 Filing: 000156459020010242 Input fundies:CapitalExpenditure: 812000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000156459020010242/itrm-20191231.xml#178750 Filing: 000156459020010242 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 77.06 million Exact value Exact value: -77056000 USD 2018-01-01 – 2018-12-31: -77056000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Iterum Therapeutics plc · 2018-12-31 Iterum Therapeutics plc (edgar:1659323) Net Income: -77056000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -77056000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000156459021012694/itrm-20201231.xml#251141 Filing: 000156459021012694 The citation records this snapshot. The page link may show a newer release later.	−USD 77.25 million Exact value Exact value: -77252000 USD 2018-01-01 – 2018-12-31: -77252000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Iterum Therapeutics plc · 2018-12-31 Iterum Therapeutics plc (edgar:1659323) Operating Cash Flow: -77252000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -77252000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000156459021012694/itrm-20201231.xml#279118 Filing: 000156459021012694 The citation records this snapshot. The page link may show a newer release later.	USD 90,000 Exact value Exact value: 90000 USD 2018-01-01 – 2018-12-31: 90000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Iterum Therapeutics plc · 2018-12-31 Iterum Therapeutics plc (edgar:1659323) Capital Expenditure: 90000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 90000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000156459021012694/itrm-20201231.xml#279746 Filing: 000156459021012694 The citation records this snapshot. The page link may show a newer release later.	−USD 77.34 million Calculation and evidence -77252000 − 90000 USD Exact free cash flow: -77342000 USD 2018-01-01 – 2018-12-31: -77252000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 90000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Iterum Therapeutics plc · 2018-12-31 Iterum Therapeutics plc (edgar:1659323) Free cash flow: -77342000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -77252000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000156459021012694/itrm-20201231.xml#279118 Filing: 000156459021012694 Input fundies:CapitalExpenditure: 90000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000156459021012694/itrm-20201231.xml#279746 Filing: 000156459021012694 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 103.13 million Exact value Exact value: -103130000 USD 2019-01-01 – 2019-12-31: -103130000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Iterum Therapeutics plc · 2019-12-31 Iterum Therapeutics plc (edgar:1659323) Net Income: -103130000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -103130000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000156459022011897/itrm-10k_20211231.htm#2992145 Filing: 000156459022011897 The citation records this snapshot. The page link may show a newer release later.	−USD 81.92 million Exact value Exact value: -81922000 USD 2019-01-01 – 2019-12-31: -81922000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Iterum Therapeutics plc · 2019-12-31 Iterum Therapeutics plc (edgar:1659323) Operating Cash Flow: -81922000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -81922000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000156459022011897/itrm-10k_20211231.htm#2872633 Filing: 000156459022011897 The citation records this snapshot. The page link may show a newer release later.	USD 24,000 Exact value Exact value: 24000 USD 2019-01-01 – 2019-12-31: 24000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Iterum Therapeutics plc · 2019-12-31 Iterum Therapeutics plc (edgar:1659323) Capital Expenditure: 24000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 24000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000156459022011897/itrm-10k_20211231.htm#2883422 Filing: 000156459022011897 The citation records this snapshot. The page link may show a newer release later.	−USD 81.95 million Calculation and evidence -81922000 − 24000 USD Exact free cash flow: -81946000 USD 2019-01-01 – 2019-12-31: -81922000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 24000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Iterum Therapeutics plc · 2019-12-31 Iterum Therapeutics plc (edgar:1659323) Free cash flow: -81946000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -81922000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000156459022011897/itrm-10k_20211231.htm#2872633 Filing: 000156459022011897 Input fundies:CapitalExpenditure: 24000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000156459022011897/itrm-10k_20211231.htm#2883422 Filing: 000156459022011897 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 52.01 million Exact value Exact value: -52006000 USD 2020-01-01 – 2020-12-31: -52006000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Iterum Therapeutics plc · 2020-12-31 Iterum Therapeutics plc (edgar:1659323) Net Income: -52006000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -52006000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017023008300/itrm-20221231.htm#3358743 Filing: 000095017023008300 The citation records this snapshot. The page link may show a newer release later.	−USD 54.53 million Exact value Exact value: -54528000 USD 2020-01-01 – 2020-12-31: -54528000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Iterum Therapeutics plc · 2020-12-31 Iterum Therapeutics plc (edgar:1659323) Operating Cash Flow: -54528000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -54528000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017023008300/itrm-20221231.htm#3217091 Filing: 000095017023008300 The citation records this snapshot. The page link may show a newer release later.	USD 11,000 Exact value Exact value: 11000 USD 2020-01-01 – 2020-12-31: 11000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Iterum Therapeutics plc · 2020-12-31 Iterum Therapeutics plc (edgar:1659323) Capital Expenditure: 11000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017023008300/itrm-20221231.htm#3228392 Filing: 000095017023008300 The citation records this snapshot. The page link may show a newer release later.	−USD 54.54 million Calculation and evidence -54528000 − 11000 USD Exact free cash flow: -54539000 USD 2020-01-01 – 2020-12-31: -54528000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 11000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Iterum Therapeutics plc · 2020-12-31 Iterum Therapeutics plc (edgar:1659323) Free cash flow: -54539000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -54528000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017023008300/itrm-20221231.htm#3217091 Filing: 000095017023008300 Input fundies:CapitalExpenditure: 11000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017023008300/itrm-20221231.htm#3228392 Filing: 000095017023008300 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 91.56 million Exact value Exact value: -91564000 USD 2021-01-01 – 2021-12-31: -91564000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Iterum Therapeutics plc · 2021-12-31 Iterum Therapeutics plc (edgar:1659323) Net Income: -91564000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -91564000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017024037615/itrm-20231231.htm#2613183 Filing: 000095017024037615 The citation records this snapshot. The page link may show a newer release later.	−USD 15.84 million Exact value Exact value: -15842000 USD 2021-01-01 – 2021-12-31: -15842000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Iterum Therapeutics plc · 2021-12-31 Iterum Therapeutics plc (edgar:1659323) Operating Cash Flow: -15842000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15842000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017024037615/itrm-20231231.htm#2525348 Filing: 000095017024037615 The citation records this snapshot. The page link may show a newer release later.	USD 61,000 Exact value Exact value: 61000 USD 2021-01-01 – 2021-12-31: 61000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Iterum Therapeutics plc · 2021-12-31 Iterum Therapeutics plc (edgar:1659323) Capital Expenditure: 61000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 61000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017024037615/itrm-20231231.htm#2532166 Filing: 000095017024037615 The citation records this snapshot. The page link may show a newer release later.	−USD 15.9 million Calculation and evidence -15842000 − 61000 USD Exact free cash flow: -15903000 USD 2021-01-01 – 2021-12-31: -15842000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 61000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Iterum Therapeutics plc · 2021-12-31 Iterum Therapeutics plc (edgar:1659323) Free cash flow: -15903000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15842000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017024037615/itrm-20231231.htm#2525348 Filing: 000095017024037615 Input fundies:CapitalExpenditure: 61000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017024037615/itrm-20231231.htm#2532166 Filing: 000095017024037615 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 44.43 million Exact value Exact value: -44434000 USD 2022-01-01 – 2022-12-31: -44434000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Iterum Therapeutics plc · 2022-12-31 Iterum Therapeutics plc (edgar:1659323) Net Income: -44434000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -44434000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2885881 Filing: 000095017025015857 The citation records this snapshot. The page link may show a newer release later.	−USD 18.47 million Exact value Exact value: -18473000 USD 2022-01-01 – 2022-12-31: -18473000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Iterum Therapeutics plc · 2022-12-31 Iterum Therapeutics plc (edgar:1659323) Operating Cash Flow: -18473000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -18473000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2771026 Filing: 000095017025015857 The citation records this snapshot. The page link may show a newer release later.	USD 62,000 Exact value Exact value: 62000 USD 2022-01-01 – 2022-12-31: 62000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Iterum Therapeutics plc · 2022-12-31 Iterum Therapeutics plc (edgar:1659323) Capital Expenditure: 62000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 62000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2780172 Filing: 000095017025015857 The citation records this snapshot. The page link may show a newer release later.	−USD 18.54 million Calculation and evidence -18473000 − 62000 USD Exact free cash flow: -18535000 USD 2022-01-01 – 2022-12-31: -18473000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 62000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Iterum Therapeutics plc · 2022-12-31 Iterum Therapeutics plc (edgar:1659323) Free cash flow: -18535000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -18473000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2771026 Filing: 000095017025015857 Input fundies:CapitalExpenditure: 62000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2780172 Filing: 000095017025015857 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 38.37 million Exact value Exact value: -38371000 USD 2023-01-01 – 2023-12-31: -38371000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Iterum Therapeutics plc · 2023-12-31 Iterum Therapeutics plc (edgar:1659323) Net Income: -38371000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -38371000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2885213 Filing: 000095017025015857 The citation records this snapshot. The page link may show a newer release later.	−USD 39.33 million Exact value Exact value: -39330000 USD 2023-01-01 – 2023-12-31: -39330000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Iterum Therapeutics plc · 2023-12-31 Iterum Therapeutics plc (edgar:1659323) Operating Cash Flow: -39330000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -39330000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2769323 Filing: 000095017025015857 The citation records this snapshot. The page link may show a newer release later.	USD 13,000 Exact value Exact value: 13000 USD 2023-01-01 – 2023-12-31: 13000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Iterum Therapeutics plc · 2023-12-31 Iterum Therapeutics plc (edgar:1659323) Capital Expenditure: 13000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 13000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2778482 Filing: 000095017025015857 The citation records this snapshot. The page link may show a newer release later.	−USD 39.34 million Calculation and evidence -39330000 − 13000 USD Exact free cash flow: -39343000 USD 2023-01-01 – 2023-12-31: -39330000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 13000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Iterum Therapeutics plc · 2023-12-31 Iterum Therapeutics plc (edgar:1659323) Free cash flow: -39343000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -39330000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2769323 Filing: 000095017025015857 Input fundies:CapitalExpenditure: 13000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2778482 Filing: 000095017025015857 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 24.77 million Exact value Exact value: -24774000 USD 2024-01-01 – 2024-12-31: -24774000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Iterum Therapeutics plc · 2024-12-31 Iterum Therapeutics plc (edgar:1659323) Net Income: -24774000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -24774000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000119312525281557/itrm-20250930.htm#1041887 Filing: 000119312525281557 The citation records this snapshot. The page link may show a newer release later.	−USD 26.77 million Exact value Exact value: -26770000 USD 2024-01-01 – 2024-12-31: -26770000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Iterum Therapeutics plc · 2024-12-31 Iterum Therapeutics plc (edgar:1659323) Operating Cash Flow: -26770000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -26770000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2767620 Filing: 000095017025015857 The citation records this snapshot. The page link may show a newer release later.	USD 2,000 Exact value Exact value: 2000 USD 2024-01-01 – 2024-12-31: 2000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Iterum Therapeutics plc · 2024-12-31 Iterum Therapeutics plc (edgar:1659323) Capital Expenditure: 2000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2776793 Filing: 000095017025015857 The citation records this snapshot. The page link may show a newer release later.	−USD 26.77 million Calculation and evidence -26770000 − 2000 USD Exact free cash flow: -26772000 USD 2024-01-01 – 2024-12-31: -26770000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 2000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Iterum Therapeutics plc · 2024-12-31 Iterum Therapeutics plc (edgar:1659323) Free cash flow: -26772000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659323?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -26770000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2767620 Filing: 000095017025015857 Input fundies:CapitalExpenditure: 2000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm#2776793 Filing: 000095017025015857 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

47 filings · 2,039 latest values · 2,039 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001659323, 1659323, ITRM, edgar:1659323

Also known as Iterum Therapeutics Ltd, Iterum Therapeutics plc

Iterum Therapeutics plc

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation